New Product - Juluca
Dolutegravir (sodium)/rilpivirine (hydrochloride) (Juluca) contains two human immunodeficiency virus (HIV) antivirals, dolutegravir (HIV integrase inhibitor) and rilpivirine (non-competitive, diarylpyrimidine non-nucleoside reverse transcriptase inhibitor (NNRTI)). Juluca is indicated for the treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of virological failure and no known or suspected resistance to any NNRTI or integrase inhibitor. Juluca therapy should be initiated by a physician experienced in the management of HIV infection. Juluca is contraindicated in combination with the following: antiarrhythmic agent dofetilide; anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin; antimycobacterials rifampicin, rifapentine; proton pump inhibitors (such as omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole); glucocorticoid systemic dexamethasone (except as a single dose treatment); St John’s wort (Hypericum perforatum). Juluca fixed dose combination tablets containing dolutegravir 50 mg (as dolutegravir sodium) and rilpivirine 25 mg (as rilpivirine hydrochloride) are available in packs of 30.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629